Dr Aparna Raina is an Early Career Researcher in the Pancreatic Cancer Translational Research Group at UNSW Sydney. She is currently involved in the SPEAR (Sulfasalazine in Patients with Pancreatic Adenocarcinoma) clinical trial, part of the Molecular Screening and Therapeutics (MoST) pancreas cancer program. As part of the clinical trial, she is helping lead the deep correlative science studies, particularly biomarker assessment in patient tissue and blood samples. Dr Raina also co-leads a SPHERE (Sydney Partnership for Health, Education, Research and Enterprise) Cancer Clinical Academic Group seed grant, investigating immune profiles in MoST-P patient specimens using multiplex immunohistochemistry. She is a trained bioinformatician, and has also developed extensive expertise in laboratory techniques, including clinically relevant 3D human pancreatic cancer explant models, immunohistochemistry, and spatial transcriptomics. During her PhD, Dr Raina explored transcriptomic and epigenetic alterations in prostate cancer, identifying two genes potentially involved in driving metastasis.